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Abstract 
Adamantinoma and osteofibrous dysplasia (OFD)-like adamantinoma are rare primary 
bone tumours that are predominantly confined to the tibia. These two entities show 
similarities in location, histology and radiological appearance; however, adamantinoma is 
malignant and therefore differentiating between these bone tumours is essential for 
optimal patient care. To elucidate their genomic and transcriptomic alteration profiles and 
expand their aetiological mechanisms, whole exome sequencing (WES) and RNA 
Sequencing (RNA-Seq) were conducted on adamantinoma and OFD-like adamantinoma 
tumours. CNV analysis using WES data revealed distinct chromosomal alteration profiles 
for adamantinoma tumours compared to OFD-like adamantinomas, allowing molecular 
differentiation between the two tumour subtypes. Combining WES and CNV analyses, the 
chromatin remodelling-related gene KMT2D was recurrently altered in 3/8 adamantinoma 
tumours (38%), highlighting the potential involvement of deregulated chromatin structure 
and integrity in adamantinoma tumourigenesis. RNA-Seq analysis revealed a novel 
somatic gene fusion (EBHB4-MARCH10) in an adamantinoma, the gene fusion was fully 
characterized. Hierarchical clustering analysis of RNA-Seq data distinctly clustered 
adamantinoma tumours from OFD-like adamantinomas, allowing to molecularly distinguish 
between the two entities. David Gene Ontology analysis of differentially expressed genes 
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identified distinct altered pathways in adamantinoma and OFD-like adamantinoma 
tumours, highlighting the different histopathological characteristics of these bone tumour 
subtypes. Moreover, RNA-Seq expression profiling analysis identified elevated expression 
of DLK1 gene in adamantinomas, serving as a potential molecular biomarker. The present 
study revealed novel genetic and transcriptomic insights for adamantinoma and OFD-like 
adamantinoma tumours, allowing to differentiate genetically and transcriptomically 
between the two lesions and identifying a potential diagnostic marker for adamantinomas.  
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Introduction  
Classic adamantinoma (henceforth referred to as adamantinoma) is a low-grade and slow-
growing primary malignant bone tumour that typically arises in long bones, predominantly 
in the mid-portion of the tibia with or without the involvement of the fibula (1, 2). The 
tumour can also occur in the fibula without the involvement of the tibia (3). Adamantinoma 
is a very rare neoplasm that represents less than 1% of all primary bone tumours (4). The 
tumour is characterised histologically by a variety of morphological patterns, consisting of 
both dominant epithelial component and areas of osteofibrous dysplasia-like fibro-osseous 
tissue (5). Adamantinoma commonly occurs in the second to fifth decade of life (median 
age 25–35) and a slight male predominance is noted (3). The initial symptoms are often 
indolent and nonspecific; however, the majority of patients present with swelling, 
symptoms may last >30 years before diagnosis (6). The tumour is locally aggressive and 
potential local recurrence or metastasis may develop years after the diagnosis of the 
primary lesion (1).  
Adamantinoma of long bone can share similarities in tumour location, radiological features 
and microscopic characteristics with two other bone lesions, osteofibrous dysplasia (OFD) 
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and OFD-like adamantinoma. OFD is a rare benign lesion involving the mid-shaft of the 
tibia with or without involvement of the fibula (2) and usually occurs at a younger age than 
adamantinoma (20 years or younger) (7). OFD-like adamantinoma tumours also arise in 
the mid-shaft of the tibia with or without the involvement of the fibula (2), characterised by 
a uniform predominance of osteofibrous dysplasia-like fibro-osseous tissue and contains 
scattered clusters of epithelial cells that are highlighted with keratin immunohistochemistry 
(6).  
In view of their overlapping clinical features, a potential histogenetic relationship between 
adamantinoma, OFD-like adamantinoma and OFD has been speculated. Of these three 
lesions, adamantinoma is considered to be on the malignant end, OFD on the benign end 
and OFD-like adamantinoma in the middle of the spectrum (3, 7). In addition, there has 
been controversial theories about the progression or regression between OFD, OFD-like 
adamantinoma and adamantinoma (7, 8). However, these relationships remain unresolved 
with little guidance from the literature.  
Recurrent genomic abnormalities involving extra copies of chromosomes 7, 8, 12, 19 or 21 
have been reported in adamantinoma and OFD-like adamantinoma, supporting a potential 
genetic relationship between these entities (3, 6). However, because of their rarity, 
comprehensive genomic studies of these two bone tumours are few and, therefore, the 
aetiology and genetic profiles of these tumours remain poorly understood. To date, no 
stringent molecular diagnostic testing is available for these bone lesions. Using whole 
exome sequencing (WES) and RNA sequencing (RNA-Seq), we performed 
comprehensive genetic and transcriptomic analyses on adamantinoma and OFD-like 
adamantinoma tumours to elucidate the genetic and transcriptomic alteration landscapes 
of these tumours. To our knowledge, the current study represents the first integrative 
genomic study using high-throughput sequencing technologies that can provide insights 
into the molecular and pathogenic mechanisms of adamantinoma and OFD-like 
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adamantinoma tumours, genetically differentiate between the two entities and guide 
personalised therapeutic development.  
 
 
Materials and methods 
 
Tumour samples  
A retrospective search of the pathology database at the Royal Orthopaedic Hospital 
(Birmingham, UK) for resected samples of adamantinoma and OFD-like adamantinoma 
was conducted. In total, eight cases with the diagnosis of adamantinoma and four OFD-
like adamantinoma samples were identified. All cases were thoroughly examined by a 
specialist bone tumour pathologist (VPS) to confirm their pathological diagnoses. Fresh 
frozen tumour sample was obtained from all cases. Six of eight adamantinoma and three 
of four OFD-like adamantinoma tumours had matched-normal samples, obtained from 
tumour-free muscle tissue adjacent to the tumour site. All samples were retrieved from the 
Royal Orthopaedic Hospital NHS Foundation Trust Tumour Bank with informed consent 
from the patient and ethical approval from institutional and local research committee 
boards. Prior to the study, all patient samples were anonymised and used in accordance 
with the ethical rules and regulations presented in the Declaration of Helsinki.  
For adamantinoma tumours, the age of the patients ranged between 7–57 (mean 34) at 
the time of diagnosis. Of these patients, five were male and three were female. The size of 
adamantinoma tumours ranged from 3–12.5 cm, majority were low grade and occurring in 
the tibia. For OFD-like adamantinoma tumours, the age of the patients ranged between 6–
15 (mean 11). All of these tumours were of low-grade, occurred in the tibia and ranged 
from 2–8.5 cm in size. 
 
	 6	
Whole exome sequencing and copy number variation analysis 
DNA from fresh frozen was extracted and purified using the DNA Isolation kit (Roche 
Diagnostic Ltd, UK) following the manufacturer’s instructions. A total of 1-3 µg of DNA from 
11 tumours (8 adamantinoma; 3 OFD-like adamantinoma) and 9 corresponding normal 
samples (6 adamantinoma; 3 OFD-like adamantinoma) were sent to Oxford Gene 
Technology (OGT, Oxford) for WES. Exons were captured using the Agilent SureSelect 
Human All Exon V5 kit (Agilent, Santa Clara, USA), following manufacturer's protocol, and 
were massively sequenced Illumina HiSeq 2000 (100-bp paired-end) or NextSeq500 (150- 
bp paired-end) platforms (Illumina, San Diego, CA, USA). One normal-paired tumour was 
exome-sequenced at SMCL Next Generation Sequencing (NGS) Hub (Cambridge, UK). 
Exons were captured by Illumina Nextera Rapid Capture Exome kit and sequenced using 
Illumina HiSeq 4000, generating 2 X 150 bp reads.  
Using WES data, copy number variation (CNV) analysis was performed on adamantinoma 
and OFD-like adamantinoma tumours using CNVkit (San Francisco, CA, USA), applying 
the tool’s default settings (https://cnvkit.readthedocs.io/en/stable/). 
 
WES analysis pipeline: reads mapping and variant calling 
Sequenced reads were aligned to the human genome reference sequence GRCh37 using 
BWA 0.7.x bioinformatic tool (9). Optical and PCR duplicates were removed using Picard 
1.x (http://picard.sourceforge.net). Somatic SNVs and indels were identified using 
VarScan2 (10) and MuTects (11) tools, applying the default settings. Variant allele 
frequency (VAF) of ≥ 10% was selected for all tumours. A series of filtering and 
prioritisation steps were followed to identify genuine somatic and pathogenic variants. In 
short, only nonsynonymous SNVs (missense, splice site, nonsense) and indels with ≥3 or 
≥5 supporting sequencing reads and ≥20% and ≥10% VAF, respectively, were prioritised. 
Variants were annotated with a modified version of Ensembl Variant Effect Predictor (12).	
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SIFT and PolyPhen2 bioinformatic tools were utilised to predict the potential pathogenic 
effect of missense substitutions and only variants that were predicted 
“deleterious/damaging” by at least one tool were retained. Variants were manually 
visualised and investigated using Integrative Genomics Viewer (IGV) and artefactual 
changes were discarded. To eliminate potential germline calls, variants were retained if 
they were novel or reported in dbSNP build 137 or the Exome Aggregation Consortium 
(ExAc) datasets with a minor allele frequency (MAF) of <0.1%. Additional stringent steps 
were applied to three tumours for which matched-normal DNA samples were not available. 
In these tumours, variants reported in dbSNP or ExAc (regardless of MAF) were 
discarded, except for variants with <0.01% MAF and described somatic in COSMIC 
database. The Catalogue Of Somatic Mutations (COSMIC) database 
(http://cancer.sanger.ac.uk/cosmic) was used to identify previously reported cancer 
mutations. COSMIC Cancer Gene Census (CCGC) consortium and Integrative Onco 
Genomics (InTOgen) database (https://www.intogen.org/search) were utilised to identify 
potential cancer driver genes. To identify potential drug-gene interactions, the Drug Gene 
Interaction Database (DGIdb) was used (http://www.dgidb.org).  
 
Pathway analysis 
Pathway analysis were performed using Ingenuity Pathway Analysis (IPA; 
http://www.ingenuity.com/) utilising the complete mutated gene list of each tumour subtype 
separately.	 IPA was run with the experimentally observed confidence filter to obtain 
significant analysis output (p-value ≤ 0.05; right tailed Fisher’s exact test). 
 
WES variant confirmation by PCR and Sanger sequencing 
DNA of the tumour and adjacent normal tissue from the same patient (when available) was 
amplified by targeting the genomic regions flanking the mutation. microCLEAN (Microzone, 
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Stourbridge, UK) was used to purify PCR products. Sanger sequencing reactions were 
performed using the BigDye v3.1 cycle sequencing kit. Prepared sequencing reactions 
were sequenced on an ABI 3730 DNA analyser (Applied Biosystems, California, USA), 
following the manufacture’s protocol. 
 
RNA Sequencing  
Total RNA from five adamantinoma and three OFD-like adamantinoma fresh frozen 
tissues was extracted using either standard TRIzol-chloroform method or Qiagen RNeasy 
Mini kit (Qiagen, Manchester, UK) following the manufacturer’s instructions. RNA-Seq was 
performed using a total of 50-100 ng of DNase-treated RNA from each tumour. The 
tumours were massively sequenced at the GenomicsBirmingham facility (Institute of 
Cancer & Genomic Sciences, University of Birmingham, Birmingham, UK). Briefly, cDNA 
libraries were constructed using the Neoprep stranded mRNA library prep (Illumina, NP-
202-1001) (Illumina, San Diego, CA, USA), according to manufacturer’s instructions. 
Prepared libraries were sequenced on NextSeq 500 (Illumina), producing paired-end 
reads (75bp in length). The Tuxedo Suite (13) was used for mapping and alignment of the 
sequenced reads (human genome reference sequence GRCh37). To identify gene 
fusions, TopHat2 (14) and STAR-Fusion (15) were used and a series of filtering steps 
were followed to identify genuine gene fusions as described in (16). The EPHB4-
MARCH10 gene fusion was validated by RT-PCR and genomically characterised using 
long range PCR (LR-PCR) as detailed in (16).  
 
RNA-Seq differential gene expression and hierarchical clustering analyses 
The alignment was performed using STAR, version 2.5.3a, on the reference genome 
GRCh38, Gencode version 28. Differential Gene Expression analysis was performed using 
the R package DESeq2, version 1.6.3, without beta. Prior assumption and applying 
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independent filtering on results. Wald test was applied to expressed genes, where 
expressed genes were defined as genes with at least 1 cpm (count per million reads) on at 
least three different samples. Significance levels were adjusted using the Benjamini-
Hochberg correction, and significant genes were defined as those genes showing an FDR 
less than 0.05. 
Principal Component Analysis was performed on zero-centred and scaled data, using the 
R package prcomp. Unsupervised clustering of the samples was performed through 
hierarchical clustering, as implemented in the R package pheatmap. Both algorithms were 
applied to the top 500 most variable expressed genes. Gene ontology analyses were 
performed with DAVID v6.8 (https://david.ncifcrf.gov/home.jsp). Functional enrichments 
were also identified with STRING v10 (17). 
 
Results  
The number of WES somatic mutations identified in adamantinoma and OFD-like 
adamantinoma tumours 
To demarcate their genomic landscape, WES was conducted on eight adamantinoma 
tumours (six normal-paired tumours and two tumours only) and four OFD-like 
adamantinoma tumours (three normal-paired tumours and one tumour-only) at an average 
coverage depth of at least 50X in each sequenced sample. A series of stringent filtering 
and prioritisation steps were followed to identify genuine somatic mutations (details in 
Materials and Methods). Following this filtering scheme, in eight adamantinoma tumours, a 
total of 21 insertions and deletions (indels) and 182 single nucleotide variants (SNVs) were 
identified, corresponding to a median of 0.84/megabase (range, 0–2.57) per coding 
megabase (Figure 1A & Supplemental Digital Content, Table S1). Somatic SNVs 
consisted of: 156 missense (85.7%), 19 nonsense (10.4%), and 7 splice site (3.8%) 
alterations. The low overall somatic mutation burden identified in adamantinomas is similar 
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to that recently documented in undifferentiated pleomorphic sarcoma of bone 
(2.2/megabase) (16), 206 soft tissue sarcomas (1.06/megabase) (18) and in Ewing 
sarcoma (0.42/megabase) (19).  
In four OFD-like adamantinoma tumours, a total of 7 indels and 59 SNVs were detected 
(Figure 1B & Supplemental Digital Content, Table S1). These SNVs comprised 54 
missense (91.5%), 3 nonsense (5.1%) and 2 splice site (3.4%) changes. Two of these 
tumours lacked any WES variants, one tumour harboured one indel only, whereas the 
fourth sample (OFD-like adamantinoma T4) harboured the remaining of the SNV and indel 
alterations. The average mutation rate in the first three OFD-like adamantinoma tumours is 
almost zero; however, taken together, in the four OFD-like adamantinoma tumours, the 
average coding mutation rate is 2.20/megabase; (Supplemental Digital Content, Table 
S1).  
 
Somatic copy number variation analysis using WES data  
Somatic CNV analyses were conducted on eight adamantinoma and four OFD-like 
adamantinoma tumours utilising WES data and using CNVkit tool. The overall somatic 
CNV heatmaps for adamantinoma and OFD-like adamantinoma tumours are shown in 
Supplemental Digital Content, Figure S1 & Figure S2, respectively. In adamantinoma 
tumours, recurrent chromosomal gains in chromosomes 7, 8, 12, and 19, consistent with 
previously published data (6). In addition, we found recurrent chromosomal gains in 
chromosomes 1q, 2, and 10 as well as recurrent chromosomal losses in chromosomes 1p, 
3, 5, 6, 15, and 17. In comparison to adamantinoma tumours, we observed no prominent 
chromosomal gains or losses in the four OFD-like adamantinoma tumours, distinguishing 
the genetic CNV profile of OFD-adamantinoma tumours from adamantinomas. 
We then assessed the CNV status of the most frequently mutated genes in all cancer 
types as reported in the COSMIC database. In adamantinoma tumours, recurrent CNV 
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gains and losses were found in BRAF (4/8; 50%), JAK2 (3/8; 38%), KRAS (3/8, 38%) 
TP53 (2/8; 25%) and EGFR (4/8; 50%) (Figure 1C). In contrast, in OFD-like 
adamantinomas, these genes were not altered, except for non-recurrent CNV losses in 
JAK2 and KRAS that were identified in OFD-like adamantinoma T4 (Figure 1C). 
KMT2D is recurrently mutated in adamantinoma tumours 
Point mutations in KMT2D (MLL2) were identified in 2/8 adamantinoma tumours (25%) 
(Figure 1C and Figure 2). The first KMT2D mutation detected, c.16154C>A; p.Ser5385Ter, 
is a nonsense change described as somatic (COSMIC database) in lung carcinoma and 
squamous cell lung carcinoma tumours (ID: COSM3954819). Using Sanger sequencing, 
this variant was confirmed somatic in sample ADA-T2 (present in tumour DNA but absent 
in the corresponding normal DNA) (Supplemental Digital Content, Figure S3). The second 
KMT2D mutation identified in ADA-T8, c.10930C>T; p.Pro3644Ser, is a missense 
substitution predicted deleterious by SIFT and PolyPhen2 in silico tools. This mutation was 
confirmed in the tumour DNA using Sanger sequencing (Supplemental Digital Content, 
Figure S3); however, no corresponding normal sample was available to confirm the 
somatic status of the mutation. Nevertheless, this mutation has not been reported 
previously in the Exome Aggregation Consortium (ExAc) or dbSNP databases (novel), 
thus increasing the likelihood of the mutation being a true somatic change.  
To assess genomic CNVs in KMT2D, the CNVkit data outputs of adamantinoma and OFD-
like adamantinoma tumours were analysed. In adamantinoma tumours, CNV gains were 
identified in two adamantinoma samples, ADA-T2 and ADA-T3. Combining SNVs and 
CNVs, KMT2D is mutated in 3/8 adamantinoma tumours (38%). By contrast, no CNV 
alterations in KMT2D were identified in OFD-like adamantinoma tumours.  
In OFD-like adamantinoma tumours, no gene was mutated in more than one sample. 
However, in OFD-like adamantinoma tumour T4, a missense substitution (c.6437C>T; 
p.Pro2146Leu) in KMT2D was identified (Figure 1C and Figure 2). This variant is 
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described as somatic (COSMIC database) in acute myeloid leukaemia and malignant 
melanoma tumours (COSM3461578). Sanger sequencing confirmed this mutation in 
tumour DNA but no DNA from corresponding normal sample was available for somatic 
status testing (Supplemental Digital Content, Figure S3). 
To infer its role in tumourigenesis and potential druggability, KMT2D was assessed 
against COSMIC, InTOgen and DGIdb databases. From the COSMIC Cancer Gene 
Census (CCGC) list, KMT2D is classified as a ‘causally implicated gene in cancer’. In 
addition, the inTOgen database categorises KMT2D as a mutational cancer driver in the 
following cancer types: prostate adenocarcinoma, bladder carcinoma, breast carcinoma, 
medulloblastoma, lung squamous cell carcinoma, and head and neck squamous cell 
carcinoma. In DGIdb, a potential drug-gene interaction for KMT2D is identified, classifying 
this gene as potentially druggable.  
Pathway analyses 
To identify putatively enriched pathways in adamantinoma and OFD-like adamantinoma 
tumours, the complete list of mutated genes of each tumour subtype was analysed using 
IPA tool. A number of significantly enriched pathways were identified in each tumour 
subtype (Supplemental Digital Content, Table S2). Calcium signalling and cell morphology 
pathways were commonly altered in both tumour subtypes.  
RNA-Seq identifies EPHB4-MARCH10 somatic gene fusion in an adamantinoma 
tumour 
RNA-Seq was performed on five adamantinoma and three OFD-like adamantinoma 
tumours, achieving a mean of 69,785,777 reads with 93.88% successful alignment rate to 
reference genome. To identify genuine somatic gene fusions, two fusion caller tools were 
used, followed by a series of filtering and prioritisation steps (see Materials and Methods). 
No somatic gene fusions were detected in OFD-like adamantinoma tumours. However, 
one somatic gene fusion, EPHB4-MARCH10, was identified in an adamantinoma tumour 
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(ADA-T4) (Figure 1C & Supplemental Digital Content, Figure S4). EPHB4-MARCH10 is a 
novel gene fusion and occurs by joining the first eight exons of the 5′-gene partner EPHB4 
(Transcript ID: ENST00000358173.3) to the last exon (exon 2) of the 3′-gene partner 
MARCH10 (Transcript ID: ENST00000582568.1) (Supplemental Digital Content, Figure S4 
A). Using RT-PCR and Sanger sequencing, this gene fusion was detected in tumour cDNA 
but not in the corresponding normal material, suggesting that the fusion is highly tumour-
specific (Supplemental Digital Content, Figure S4 B). Genomic characterisation analysis 
using LR-PCR and Sanger sequencing for EPHB4-MARCH10 was performed 
(Supplemental Digital Content, Figure S4 C & D). The gene fusion was confirmed in the 
tumour DNA but was not detected in corresponding normal material, confirming the 
somatic status of the fusion. Genomic breakpoint analysis indicated that this gene fusion 
occurs as a result of a genomic translocation rearrangement between chromosomes 7 and 
17, fusing the fusion gene partners. The EPHB4-MARCH10 chimeric transcript is in-frame 
and the predicted translated chimeric product is 640 amino acid in length, consisting of 
529 amino acids from EPHB4 and 111 amino acids belonging to MARCH10 (Figure 3). In 
this chimeric transcript, the organisation of the protein domains of EPHB4 is as follows: the 
ephrin receptor ligand binding, putative ephrin-receptor like and fibronectin type III 
(repeats) functional domains are retained, while ephrin type-A receptor 2 transmembrane, 
catalytic protein tyrosine kinase and sterile alpha motif domains are completely lost (Figure 
3). Using DGIdb, multiple drug-gene interactions were identified for EPHB4, classifying this 
gene as a potential drug target.  
Hierarchical clustering and differential expression analyses using RNA-Seq data 
Using RNA-Seq data, unsupervised hierarchical clustering analysis was performed on five 
adamantinoma and three OFD-like adamantinoma tumours. The tumours of each lesion 
subtype distinctly clustered together, thus molecularly distinguishing adamantinoma from 
OFD-like adamantinoma tumours (Figure 4A). 
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Supervised differential expression analysis of adamantinoma versus OFD like 
adamantinoma highlighted DLK1, Delta Like Non-Canonical Notch Ligand 1, as a 
specifically expressed gene in adamantinomas. The complete list of differentially 
expressed genes is provided in Supplemental Digital Content, Table S3. David Gene 
Ontology analyses of specific genes expressed in adamantinoma and OFD-like 
adamantinoma tumours identified strong enrichment of genes involved in 
epidermis/epithelium development and collagen biosynthesis and modifying enzymes, 
respectively (Figure 4 B, C). The tumor-specific enrichments of genes involved in the 
development/organization of epithelium and bone were confirmed with STRING tool. This 
last analysis also suggested an increased kinase activity for Adamantinomas 
(Supplemental Digital Content, Table 4). 
 
Discussion 
In the current study, we investigated the genetic and transcriptomic alteration landscapes 
in adamantinoma and OFD-like adamantinoma bone tumours using WES and RNA-Seq 
technologies We compared the transcriptomic profiles of adamantinoma and OFD-like 
adamantinoma tumours and identified a potential biomarker for adamantinoma tumours.  
WES was conducted on eight adamantinoma and four OFD-like adamantinoma tumours. 
In OFD-like adamantinoma tumours, no recurrent gene mutations or somatic gene fusions 
were identified. Moreover, no prominent chromosomal gains or losses were detected in 
these tumours in comparison to adamantinomas. By contrast, in adamantinoma tumours, 
KMT2D was mutated in 38% of the samples. In addition, multiple recurrent chromosomal 
gains and losses (novel and previously reported) were identified in adamantinoma 
samples these included gains and losses in well-known cancer genes (BRAF, JAK2, 
KRAS, TP53, and EGFR).  
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In adamantinoma tumours, KMT2D was recurrently mutated (3/8 tumours; 38%), for which 
two tumours harboured two SNVs and two tumours exhibited CNV gains. KMT2D, 
encoding histone lysine N-methyltransferase 2D, is a histone-modifier gene that plays an 
important role in regulating chromatin structures and DNA accessibility. Many somatic 
mutations in KMT2D have been reported in multiple cancers, including non-Hodgkin 
lymphomas (20), acute myeloid leukaemia, lung carcinomas (21) and histiocytic sarcoma 
(22). Moreover, KMT2D is one of the most frequently mutated genes in multiple paediatric 
malignancies (23). Here, we report for the first time the association of KMT2D alterations 
in adamantinoma bone tumours, linking the potential role of epigenetic regulation in the 
pathogenesis of this tumour subtype.  
The majority of KMT2D reported mutations are nonsense or frameshift changes that are 
predicted to produce truncated products (24). In the ADA-T2 sample of the current study, 
we report a nonsense (truncating) mutation (c.16154C>A; p.Ser5385Ter) occurring just 
upstream of the SET domain, thus producing a protein product that lacks the entire SET 
domain at the C-terminus (Figure 2). Frameshift and nonsense changes that affect the 
SET domain account for 37% of total KMT2D mutations (24). The enzymatically active 
SET domain has an important role in H3K4 methyltransferase activity (25). Set1-containing 
lysine methyltransferases (KMTs), including KMT2D, are part of large highly conserved 
multicomponent complexes known as SET/COMPASS (COMplex of Proteins ASsociated 
with Set) (26). The SET/COMPASS complexes are key regulators for the majority of global 
H3K4 dimethylation and trimethylation, which play a role in gene expression regulation 
(27).  
To infer the potential pathological role of SET domain in mice, a study by (28) inactivated 
the methyltransferase activity of Kmt2C (Kmt2CΔSET/ΔSET), a closely related paralogue to 
Kmt2D with extended SET domain similarity. The Kmt2CΔSET/ΔSET mice showed incomplete 
embryonic lethality and exhibited cellular hyperproliferation and kidney ureter urothelium 
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tumours, accompanied with increased levels of DNA damage. Therefore, the truncating 
KMT2D mutation reported in the current study, which leads to complete loss of the SET 
domain, is likely tumourigenesis-related and is possibly characterised by loss or reduced 
tumour suppressing activity. 
The second recurrent KMT2D missense mutation identified in ADA-T8 (c.10930C>T; 
p.Pro3644Ser) does not reside in, or in close proximity of annotated functional domains of 
KMT2D (Figure 2). Further investigations are required to elucidate the pathological role of 
this mutation.  
In an OFD-like adamantinoma tumour (T4), the missense mutation (c.6437C>T; 
p.Pro2146Leu) in KMT2D is located in close proximity of the high mobility group (HMG-I) 
domain (Figure 2). HMG-I domain is comprised of short motifs that interact with the minor 
groove of DNA sequences, thus regulating DNA replication and transcription (24).  
In the second part of the study, we aimed to identify somatic gene fusions arising from 
chromosomal rearrangements in five adamantinoma and three OFD-like adamantinoma 
tumours. As mentioned earlier, no genuine somatic gene fusions were identified in OFD-
like adamantinoma samples. In contrast, in adamantinoma tumours, a novel somatic gene 
fusion (EPHB4-MARCH10) was detected, validated as highly tumour-specific by RT-PCR, 
characterised genomically and confirmed somatic at the DNA level using LR-PCR. 
EPHB4-MARCH10 gene fusion was identified in ADA-T4 sample that lacked KMT2D SNV 
or CNV alterations. The EPHB4 gene encodes a receptor tyrosine kinase (RTK) that 
belongs to the erythropoietin-producing hepatocellular carcinoma (Eph) family, the largest 
class of RTKs (29). RTKs are transmembrane proteins that regulate key biological 
processes, including cell differentiation and proliferation. Impaired Eph/ephrin cellular 
interactions have been implicated in carcinogenesis, contributing to tumour growth, 
metastasis, chemoresistance and tumour angiogenesis (30). Mutations in EPHB4 have 
been reported in several lung cancers including lung adenocarcinoma and small cell lung 
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cancer (31). MARCH10 belongs to the MARCH family membrane-bound E3 ubiquitin 
ligases that are involved in endocytosis, protein sorting and lysosomal degredation (32). 
Bidirectional signalling is a hallmark of the Eph receptor and ephrin ligand signalling 
system which consists of forward signalling in receptor-expressing cells and reverse 
signalling in ligand-expressing cells (33). The Eph/ephrin signalling network regulates cell 
morphology, adhesion, migration and, in the context of tumour growth, this signalling 
network promotes tumour growth, invasiveness and tumour angiogenesis (30). In cancer 
cells, the role of EPHB4 is complex; however, both tumour-suppressing and tumour-
promoting (oncogenic) activities have been described (34). In the EPHB4-MARCH10 
fusion reported in the current study, three of EPHB4 functional domains are completely 
lost, thus possibly interfering with the Eph/ephrin bidirectional system. Nevertheless, 
further investigations are needed to determine the pathological role of this gene fusion. 
Unsupervised clustering analysis using RNA-Seq data distinctly clustered the tumours 
adamantinoma and OFD-like adamantinoma subtypes, confirming their pathological 
diagnoses and allowing for molecular differentiation between these tumour subtypes. The 
clustering analysis can be beneficial for tumours such as OFD-like adamantinoma T4 for 
which a mutational profile is similar to those in adamantinomas.   
Supervised differential expression profiling of adamantinoma and OFD-like adamantinoma 
tumours revealed an elevated expression of DLK1 in the former bone tumour subtype. 
DLK1 is a member of the Epidermal Growth Factor (EGF)-like repeat-containing family of 
proteins. DLK1 protein plays a role in modulating adipogenesis (35) and regulating 
osteoblast differentiation (36). Abberant expression of DLK1 has been observed in multiple 
human cancers, including neuroblastoma (37) and human prostate cancer (38). A study by 
(39) assessed the expression of Dlk1 in tumours derived from skeletal muscle, adipose 
tissue and bone. The authors identified Dlk1 expression in skeletal muscle derived 
tumours (18/21 cases) and liposarcomas (adipose tissue tumours; 5/19); however, no 
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expression of Dlk1 was observed in nine bone-derived tumours (osteogenic sarcoma, 
osteoblastoma, osteochondroma). In the current study, the elevated expression of DLK1 in 
adamantinomas can serve as a molecular biomarker specific to this tumour subtype that 
can be diagnostically utilised in clinics; nevertheless, additional confirmatory experiments 
are required.  
The results of David and STRING analyses correlated with the different histopathological 
characteristics of the two tumor types (40). In fact, enrichments of genes involved in the 
development/organization of epithelium and bone were identified for Adamantinomas and 
OFD-like adamantinomas, respectively. Moreover, the identification of increased kinase 
activity in adamantinomas can suggest therapeutic targets for these tumors. Of note, 
cases of metastatic adamantinomas responding to kinases inhibitors have already been 
described (41, 42). 
In conclusion, the current study represents the first comprehensive genetic and 
transcriptomic alteration landscapes of adamantinoma and OFD-like adamantinoma 
tumours using NGS technologies, indicating a genetic differentiation between these two 
entities and expanding our understanding of their aetiology and pathology. We reported 
KMT2D as a novel recurrently mutated gene in adamantinoma tumours, highlighting the 
role of deregulated chromatin remodelling mechanisms in pathogenesis of 
adamantinomas and providing insights into developing KMT2D targeted therapeutics. In 
addition, we identified a novel EPHB4-MARCH10 somatic gene fusion that may be a 
tumour driver. Overall, we showed different genetic and transcriptomic profiles for 
adamantinoma and OFD-like adamantinoma tumours, therefore molecularly differentiating 
between these two bone tumour subtypes. The elevated expression of DLK1 identified in 
adamantinoma tumours may serve as a potential diagnostic biomarker. However, the 
small cohort size is a limitation of this study and finding additional cases for these ultra-
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Figure 1. The total number of somatic alterations and WES and RNA Sequencing 
alterations landscape  in adamantinoma and OFD-like adamantinoma tumours. The 
total somatic alterations in (A) adamantinomas and (B) OFD-like adamantinoma tumours, 
single nucleotide variants (SNVs) consist of missense alterations that are predicted 
deleterious by at least one in silico tool (SIFT or PolyPhen2), nonsense and splice site 
changes. INDELs consist of small in-frame or out-of-frame insertions or deletions. (C) The 
WES and RNA alterations landscape of OFD-like and adamantinoma tumours. WES was 
conducted on eight adamantinoma and four OFD-like adamantinoma tumours. KMT2D 
was mutated in two adamantinoma samples. RNA-sequenced samples are underlined. 
ADA: adamantinoma; OFD-like: OFD-like adamantinoma. ADA: adamantinoma; OFD-like: 
OFD-like adamantinoma.  
Figure 2. Somatic KMT2D mutations and their relative protein positions identified in 
adamantinoma and OFD-like adamantinoma tumours. The black balls resemble 
mutations and their amino acid (AA) locations. Two KMT2D mutations were identified in 
two adamantinoma tumours (S5385Ter, nonsense;  P3644S, missense). One KMT2D 
mutation was detected in an OFD-like adamantinoma tumour (P2146L; missense). Zf-HC: 
PHD-like zinc-binding domain; PHD: PHD zinc finger; HMG-I: high-mobility-group (HMG)-
box domain; SET: SET domain. 
Figure 3. The protein domain organization of the gene partners of EPHB4-MARCH10 
gene fusion. The grey shaded area resembles the retained protein domains of the fused 
exons of EPHB4 and MARCH10 gene partners. The gene fusion breakpoints are denoted 
by a black double slash. The gene fusion is in-frame, resulting from joining the first 529 
amino acids of EPHB4 to the last 111 amino acids of MARCH10.  
Figure 4. Unsupervised and supervised analysis of adamantinoma and OFD-like 
adamantinoma tumours using RNA-Seq data. (A) Un supervised clustering analysis of 
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adamantinoma and OFD-like adamantinoma tumours clearly clustered the tumours of 
each subtype in two groups. David Gene Ontology analyses of differentially expressed 
genes for (B) adamantinoma and (C) OFD-like adamantinoma tumours indicated strong 
enrichment for genes involved in epidermis development and collagen biosynthesis and 
modifying enzymes, respectively.  
 
Supplemental table and figure legends. 
Table S1. Coding mutation rate of adamantinoma and OFD-like adamantinoma 
tumours. The mutational rate is calculated by dividing the number of identified mutations 
by the total length of the exome (30 megabase). ADA: adamantinoma; OFD-like: OFD-like 
adamantinoma. 
Table S2. Canonical and bio function pathways affected in adamantinoma and OFD-
like adamantinoma tumours. Pathway analysis was performed using Ingenuity Pathway 
Analysis (IPA) software, utilising the complete mutated gene list of each tumour subtype 
separately. 
Table S3. List of differentially expressed genes of adamantinoma versus OFD-like 
adamantinma. Genes overexpressed in adamantinoma tumous have ‘1’ significance, 
whereas genes overexpressed in OFD-like adamantinoma tumours have ‘-1’ significance.  
Table S4. Functional enrichment of genes in the Adamantinoma and OFD-like 
Adamantinoma networks identified by STRING v10. Only the top 10 results in the 
Biological Process, Cellular Component and Molecular function GO categories are shown. 
Figure S1. Somatic copy number variation heatmap of adamantinoma tumours. 
Genomic gains and losses regions were identified by CNVkit tool using WES data. ADA: 
adamantinoma. 
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Figure S2. Somatic copy number variation heatmap of OFD-like adamantinoma 
tumours. Genomic gains and losses regions were identified by CNVkit tool using WES 
data. OFD-like: OFD-like adamantinoma.  
Figure S3. Sanger sequencing confirmation of KMT2D mutations in adamantinoma 
and OFD-like adamantinoma tumours. ADA: adamantinoma; OFD-like: OFD-like 
adamantinoma. 
Figure S4. Schematic representation and validation of EPHB4-MARCH10 gene 
fusion. (A) The genomic structure of gene fusions partners, EPHB4 (orange) and 
MARCH10 (blue). (B) Sanger sequencing validation of the gene fusion, confirming the 
fusion breakpoint at the cDNA level (by RT-PCR) and showing an in-frame chimeric 
product. (C) Diagrammatic representation of the gene fusion at the genomic (43) level and 
mapping of the gene fusion breakpoints. (D) LR-PCR analysis using Sanger sequencing 
confirming the gene fusion breakpoints at the DNA level, resulting from a translocation 
between chromosomes 7 and 17. 
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